OBJECTIVETo investigate the tumor targeting efficacy of (18)F-AlF-NOTA-PRGD2, a novel radiotracer of Arginine-glycine-aspartic acid (RGD) peptides.

METHODS(18)F-AlF-NOTA-PRGD2 was synthesized in one-step by conjugating NOTA-PRGD2 with (18)F-AlF at 100 degrees celsius;. The tumor targeting efficacy and in vivo biodistribution profile of (18)F-AlF-NOTA-PRGD2, following intravenous injection via the tail vein, were evaluated in a nude mouse model bearing subcutaneous U87MG glioblastoma xenograft by radioactivity biodistribution assessment, PET/CT and microPET/CT.

RESULTSNOTA-PRGD2 was (18)F-fluorinated successfully in one-step with a yield of 17%-25% within 15-20 min. Radioactivity biodistribution study confirmed the tumor-targeting ability of (18)F-AlF-NOTA-PRGD2 in the tumor-bearing mice. At 1 and 2 h following injection, (18)F-AlF-NOTA-PRGD2 uptake in the tumor reached 4.14∓1.44 and 2.80∓1.18 % ID/g (t=1.910, P=0.070) with tumor/brain ratios of 2.95∓0.61 and 5.21∓2.62, respectively (t=-1.686, P=0.167). Both PET/CT and microPET/CT were capable of showing the radioactivity biodistribution of (18)F-AlF-NOTA-PRGD2 in the mouse model and clearly displayed the tumor, but microPET/CT showed a much better image quality.

CONCLUSION(18)F-AlF-NOTA-PRGD2 prepared by one-step radiosynthesis can selectively target to the tumor, demonstrating its potential as a good radiotracer for tumor imaging.

Animals ; Cell Line, Tumor ; Fluorine Radioisotopes ; Glioblastoma ; diagnostic imaging ; Humans ; Mice ; Mice, Nude ; Oligopeptides ; Positron-Emission Tomography ; methods ; Radioactive Tracers

Esophageal squamous cell papillomatosis is a rare disorder that is usually found incidentally on an upper gastrointestinal endoscopy examination or autopsy. A 70-year-old woman presented with a two-month history of dysphagia and abdominal discomfort. A chest CT scan showed diffuse marked thickening of the esophageal wall along the entire length and multiple small enhancing polypoid projections in the distal esophagus. Diffuse circumferential FDG uptake in the entire esophagus was seen on [18F] FDG PET/CT. Squamous papillomatosis was diagnosed by an endoscopic biopsy. We report a case of extensive esophageal papillomatosis with imaging features on CT and [18F] FDG PET/CT, with a review of the clinical literature.
Aged ; Autopsy ; Biopsy ; Deglutition Disorders ; Endoscopy, Gastrointestinal ; Esophagus ; Female ; Fluorine Radioisotopes ; Humans ; Papilloma ; Positron-Emission Tomography ; Thorax ; Tomography, X-Ray Computed

Escherichia coli ; enzymology ; Fluorine Radioisotopes ; analysis ; Lipid Bilayers ; chemistry ; Magnetic Resonance Spectroscopy ; Maleates ; chemistry ; Nanoparticles ; chemistry ; Phosphorylation ; Polystyrenes ; chemistry ; Protein Conformation ; Protein-Tyrosine Kinases ; chemistry ; metabolism ; Tyrosine ; metabolism

OBJECTIVE: The aim of the study was to compare the diagnostic performances of F-18 sodium fluoride positron emission tomography/computed tomography (bone PET/CT) and bone scintigraphy (BS) for the detection of thyroid cancer bone metastasis. MATERIALS AND METHODS: We retrospectively enrolled 6 thyroid cancer patients (age = 44.7 ± 9.8 years, M:F = 1:5, papillary:follicular = 2:4) with suspected bone metastatic lesions in the whole body iodine scintigraphy or BS, who subsequently underwent bone PET/CT. Pathologic diagnosis was conducted for 4 lesions of 4 patients. RESULTS: Of the 17 suspected bone lesions, 10 were metastatic and 7 benign. Compared to BS, bone PET/CT exhibited superior sensitivity (10/10 = 100% vs. 2/10 = 20%, p = 0.008), and accuracy (14/17 = 82.4% vs. 7/17 = 41.2%, p < 0.025). The specificity (4/7 = 57.1%) of bone PET/CT was not significantly different from that of BS (5/7 = 71.4%, p > 0.05). CONCLUSION: Bone PET/CT may be more sensitive and accurate than BS for the detection of thyroid cancer bone metastasis.
Adult ; Bone Neoplasms/*radiography/secondary ; Bone and Bones/*radiography ; Contrast Media/*chemistry ; Female ; Fluorine Radioisotopes/chemistry ; Humans ; Male ; Middle Aged ; Positron-Emission Tomography ; Retrospective Studies ; Sodium Fluoride/*chemistry ; Thyroid Neoplasms/*pathology ; Tomography, X-Ray Computed ; Whole Body Imaging

A 50-yr-old man presented with intermittent hemoptysis and was diagnosed small cell lung cancer. 18F-FDG PET/CT for staging demonstrated extensive hypermetabolic lesions throughout the skeleton and liver. Interestingly, skeletal muscles of limbs, mediastinum, bowel, and especially brain showed very low FDG uptake. Because of some characteristics in common with super scan on skeletal scintigraphy, this case could be considered as 'metabolic super scan'.
Carcinoma, Small Cell/complications/radionuclide imaging ; Fluorine Radioisotopes/diagnostic use ; Fluorodeoxyglucose F18/*diagnostic use ; Hemoptysis/complications/radionuclide imaging ; Humans ; Liver Neoplasms/diagnosis/secondary ; Lung Neoplasms/complications/radionuclide imaging ; Male ; Middle Aged ; *Positron-Emission Tomography ; Radiopharmaceuticals/*diagnostic use

OBJECTIVETo investigate the biodistribution of (18)-NaF as an imaging agent for position emission tomography (PET) in rat models of osteoporosis.

METHODSOsteoporosis was induced in 10 rats via injection with an excess of dexamethasone phosphate sodium, and the biodistribution of (18)-NaF in the rats was studied, with another 10 normal rats as the control group. (18)-NaF PET was also performed in 8 healthy volunteers, and the uptakes of (18)-F- in the bone tissues were measured.

RESULTSCompared with the control rats, the osteoporotic rats showed significantly decreased (18)-F- uptake, especially in the femoral neck, lumbar vertebrae, the 7th rib and the tibia (P<0.05). Dynamic chest PET scanning in the volunteers revealed obvious (18)-F- uptake in the spine, ribs and humerus 20 s after injection of the imaging agent. (18)-F- uptake significantly increased with time in the bones, reaching the peak level 60 min after the injection, and whole-body PET at this point demonstrated obvious skeletal (18)-F- uptake, with high skeletal-to-muscle (STM) ratio that averaged 8.12.

CONCLUSION(18)-NaF is an excellent skeletal imaging agent for clinical skeletal blood flow and metabolism measurements. The uptake of (18)-NaF has significant difference between normal and osteoporotic bone tissues, indicating the value of (18)-NaF PET for study of osteoporosis.

Adult ; Animals ; Bone and Bones ; diagnostic imaging ; metabolism ; Female ; Fluorine Radioisotopes ; pharmacokinetics ; Humans ; Male ; Osteoporosis ; diagnostic imaging ; Positron-Emission Tomography ; methods ; Radiopharmaceuticals ; pharmacokinetics ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Sodium Fluoride ; pharmacokinetics ; Tissue Distribution

Dideoxynucleosides ; False Positive Reactions ; Fluorine Radioisotopes ; Fluorodeoxyglucose F18 ; Humans ; Inflammation ; diagnosis ; Neoplasm Staging ; Neoplasms ; diagnosis ; metabolism ; pathology ; radiotherapy ; Positron-Emission Tomography ; methods ; Radiotherapy, Intensity-Modulated ; Sensitivity and Specificity ; Tomography, X-Ray Computed ; Treatment Outcome

OBJECTIVETo develop a 18F-labeled amino acid, O-(2-[18F]fluoroethyl) - L-tyrosine(18F-FET), as a positron emission tomography (PET) tracer for imaging cerebral tumors.

METHODS18F-FET was synthesized. Preclinical studies including sterility, endotoxin, and toxicity tests were performed. Two brain tumor cases were studied using 18F-FET and compared with 18F-FDG.

RESULTSRadiochemical purity of 18F-FET was over 95% which remained stable for 6 hours. The 18F-FET injection was sterile and its endotoxin content accorded with the standards of Chinese Pharmacopoeia. The uptake of 18F-FET in the normal brain tissues was significantly lower than that of the tumor, and the images of the brain tumor were clearer than those of 18F-FDG.

CONCLUSION18F-FET can accumulate in the tumor tissues to give high quality images. It suggests that 18F-FET may be a safe and effective tracer for brain tumor imaging.

Adult ; Animals ; Brain Neoplasms ; diagnostic imaging ; Female ; Fluorine Radioisotopes ; Fluorodeoxyglucose F18 ; Glioblastoma ; diagnostic imaging ; Humans ; Male ; Mice ; Middle Aged ; Sarcoma 180 ; diagnostic imaging ; Tomography, Emission-Computed ; Tyrosine ; analogs & derivatives ; chemical synthesis

OBJECTIVETo study the role and prospect of 18FDG PET imaging in patients with malignant lymphoma.

METHODSForty-four patients (73 studies) with malignant lymphoma underwent 18FDG PET imaging. Final diagnoses were proved histopathologically. Images obtained were analyzed using visual and semiquantitative analysis (SUV).

RESULTSEither nodal or extranodal tumor foci showed high 18FDG uptake. 18FDG PET led to correct diagnosis in 5 of 6 cases except 1 false negative case. PET imaging changed the staging in 4 of 6 cases pretherapeutically. Of the 16 cases in which either residual tumor mass or suspicious recurrence suggested by other imaging modalities, 18FDG PET confirmed relapse in 5, detected more lesions in 2 and showed no evidence of active tumor mass in 9. For the 3 patients with comparison between pre- or post-treatment PET imaging and 16 patients who only underwent post-treatment PET follow-up studies, therapeutic response was correctly evaluated.

CONCLUSIONS18FDG PET is a valuable non-invasive metabolic imaging modality in facilitating diagnosis and staging, evaluating therapeutic response, assessing clinical outcome and predicting prognosis in patients with lymphoma.

Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Female ; Fluorine Radioisotopes ; Fluorodeoxyglucose F18 ; Follow-Up Studies ; Humans ; Lymphoma, Non-Hodgkin ; diagnostic imaging ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; diagnostic imaging ; Neoplasm Staging ; Prognosis ; Radiopharmaceuticals ; Retrospective Studies ; Tomography, Emission-Computed

Escherichia coli ; chemistry ; cytology ; Fluorine Radioisotopes ; MAP Kinase Kinase 5 ; chemistry ; metabolism ; MAP Kinase Kinase Kinase 3 ; chemistry ; metabolism ; Nuclear Magnetic Resonance, Biomolecular ; Protein Binding ; Protein Interaction Mapping ; methods ; Protein Interaction Maps